Today, TAAR1 is being actively studied in the context of mental and neuropsychiatric diseases, and TAAR1 agonists are being considered therapeutic agents for schizophrenia, anxiety, and depression treatment [6,7,8,9]. The gene discussed is TAAR1; the disease is major depressive disorder.